DPT Laboratories To Integrate With Confab - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

DPT Laboratories To Integrate With Confab

The CDMOs DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, have integrated under the leadership of Paul Johnson, group president and COO. Both DPT and Confab are owned by Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.

The integration includes a rebranding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s sales and marketing team to introduce Confab’s experts in complex solid, semi-solid, and liquid dosage forms to new pharmaceutical industry clients, especially in the US market. The management teams for both companies will remain inplace, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson. DPT has additional R&D and manufacturing facilities in Lakewood, New Jersey.

Source: DPT Laboratories


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here